Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 1,113,568 | $69,820,712 | -16% | 0.02% |
| 2. | 1,379,000 | $1,428,561 | 0.06% | ||
| 3. | IvyRock Asset Management Charles Huang | 7,000 | $438,900 | -18% | 0.25% |
| 4. | Bayforest Capital Theodoros Tsagaris | 237 | $14,860 | +339% | 0.02% |
| 5. | Lynx1 Capital Management Weston Nichols | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 500 | $11,000.00 | 36,080 | 2024-04-18 | Filing | |
| $25.00 | 500 | $12,500.00 | 35,580 | 2024-04-10 | Filing | |
| $27.34 | 150 | $4,101.00 | 35,080 | 2024-04-02 | Filing | |
| $27.50 | 850 | $23,375.00 | 34,930 | 2024-03-26 | Filing | |
| $28.00 | 400 | $11,200.00 | 34,080 | 2024-03-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.92 | 8,730 | $627,861.60 | 162,905 | 2026-04-22 | Filing | |
| $70.45 | 1,157 | $81,510.65 | 171,635 | 2026-04-22 | Filing | |
| $70.11 | 3,208 | $224,912.88 | 172,792 | 2026-04-22 | Filing | |
| $75.00 | 10,000 | $750,000.00 | 226,958 | 2026-04-23 | Filing | |
| $64.19 | 10,000 | $641,900.00 | 236,958 | 2026-03-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,146,136 | $448,062,727 | 0.02% | |
| 2. | 6,032,416 | $378,232,483 | 0.01% | |
| 3. | 1,336,271 | $83,784,191 | 0.01% | |
| 4. | 1,273,266 | $79,612,179 | 0.08% | |
| 5. | 965,775 | $60,554,093 | 0.02% |
News See All
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its...
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a relatively recent addition to the 13F portfolio of Fisher Asset Management.
Billionaire Ken Fisher's 15 Most Notable Moves for 2026
For many Wall Street investors, it is their first time navigating market uncertainty at a time of geopolitical upheaval.
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires.
12 Best Multibagger Stocks to Invest In According to Billionaires
On March 11, Tom Lee of Fundstrat joined 'Closing Bell' on CNBC to discuss his market outlook amid rising oil prices and sector volatility.
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited
TheFly reported on February 6 that Morgan Stanley lowered its price target for ARWR to $78 from $81 and kept an Equal Weight rating.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript February 5, 2026Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data
TheFly reported on January 13 that Piper Sandler lifted its price target on ARWR to $110 from $100, and reiterated an Overweight rating.
Hedge Fund Resource Center